Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
Ascendis Pharma (Nasdaq: ASND) has scheduled its second quarter 2025 financial results announcement and business update for Thursday, August 7, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day.
Investors can access the live webcast through the company's investor relations website, and a replay will be available for 30 days following the event. Participants interested in the teleconference can register in advance through the provided link.
Ascendis Pharma (Nasdaq: ASND) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 e l'aggiornamento aziendale per giovedì 7 agosto 2025, dopo la chiusura del mercato statunitense. La società terrà una conference call e una trasmissione in webcast alle 16:30 ET dello stesso giorno.
Gli investitori potranno seguire il webcast in diretta tramite il sito web delle relazioni con gli investitori della società, e una replica sarà disponibile per 30 giorni dopo l'evento. I partecipanti interessati alla teleconferenza possono registrarsi in anticipo tramite il link fornito.
Ascendis Pharma (Nasdaq: ASND) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 y una actualización empresarial para el jueves 7 de agosto de 2025, después del cierre del mercado estadounidense. La compañía realizará una llamada de conferencia y una transmisión en webcast a las 4:30 p.m. ET del mismo día.
Los inversores podrán acceder al webcast en vivo a través del sitio web de relaciones con inversores de la empresa, y una repetición estará disponible durante 30 días después del evento. Los participantes interesados en la teleconferencia pueden registrarse con anticipación mediante el enlace proporcionado.
Ascendis Pharma (Nasdaq: ASND)는 2025년 2분기 재무 실적 발표 및 사업 업데이트를 2025년 8월 7일 목요일 미국 시장 마감 후에 예정했습니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 회사의 투자자 관계 웹사이트를 통해 라이브 웹캐스트에 접속할 수 있으며, 이벤트 후 30일 동안 다시보기가 제공됩니다. 전화회의에 참가를 원하는 분들은 제공된 링크를 통해 사전 등록할 수 있습니다.
Ascendis Pharma (Nasdaq : ASND) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 et une mise à jour commerciale pour le jeudi 7 août 2025, après la clôture du marché américain. La société organisera une conférence téléphonique et une webdiffusion à 16h30 ET le même jour.
Les investisseurs pourront accéder à la webdiffusion en direct via le site des relations investisseurs de la société, et un replay sera disponible pendant 30 jours après l'événement. Les participants intéressés par la téléconférence peuvent s'inscrire à l'avance via le lien fourni.
Ascendis Pharma (Nasdaq: ASND) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 sowie ein Unternehmensupdate für Donnerstag, den 7. August 2025, nach Börsenschluss in den USA, geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten.
Investoren können den Live-Webcast über die Investor-Relations-Website des Unternehmens verfolgen, und eine Aufzeichnung wird für 30 Tage nach der Veranstaltung verfügbar sein. Teilnehmer, die an der Telefonkonferenz interessiert sind, können sich im Voraus über den bereitgestellten Link anmelden.
- None.
- None.
COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on August 7, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its second quarter 2025 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (ii) Ascendis’ application of TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. © July 2025 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Sarada Weerasinghe | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| ir@ascendispharma.com | media@ascendispharma.com |
| Patti Bank | |
| ICR Healthcare | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com |
FAQ
When will Ascendis Pharma (ASND) report Q2 2025 earnings?
How can investors access Ascendis Pharma's Q2 2025 earnings call?
Where can I find the replay of Ascendis Pharma's Q2 2025 earnings webcast?
What time is Ascendis Pharma's Q2 2025 earnings call?
